Federated Hermes Inc. Has $185,000 Stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Federated Hermes Inc. decreased its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 23.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 340,693 shares of the biopharmaceutical company’s stock after selling 103,255 shares during the period. Federated Hermes Inc.’s holdings in Sangamo Therapeutics were worth $185,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Miracle Mile Advisors LLC bought a new stake in Sangamo Therapeutics during the 3rd quarter valued at approximately $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in Sangamo Therapeutics during the 3rd quarter valued at approximately $26,000. Mackenzie Financial Corp boosted its stake in Sangamo Therapeutics by 72.4% during the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 31,003 shares during the period. SG Americas Securities LLC boosted its stake in Sangamo Therapeutics by 255.2% during the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 63,612 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Sangamo Therapeutics by 10.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 676,189 shares of the biopharmaceutical company’s stock valued at $406,000 after purchasing an additional 62,465 shares during the period. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Trading Up 6.5 %

Shares of SGMO stock opened at $0.56 on Monday. The stock has a 50 day moving average of $0.71 and a two-hundred day moving average of $0.59. Sangamo Therapeutics, Inc. has a 12 month low of $0.29 and a 12 month high of $1.67. The company has a market capitalization of $115.33 million, a P/E ratio of -0.38 and a beta of 1.40.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). The firm had revenue of $2.04 million during the quarter, compared to the consensus estimate of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. Sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on SGMO shares. Royal Bank of Canada restated a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, March 14th. HC Wainwright restated a “buy” rating and set a $5.00 target price (up previously from $3.00) on shares of Sangamo Therapeutics in a research note on Tuesday, March 19th. Finally, StockNews.com started coverage on Sangamo Therapeutics in a research note on Saturday, April 27th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $5.67.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.